Another interesting way to potentially harness the power of the Bragg peak is in the treatment of young men with early stage testicular seminoma. This dosimetric analysis of 24 consecutive patients (median age 38) receiving proton therapy for stage I-IIA mostly recurrent seminoma demonstrates significantly lower mean doses to the kidneys, stomach, bowel, liver, bladder, and total body with delivered photon plans compared to post-hoc generated 3D and IMRT/VMAT plans resulting in significantly lower predicted risks of secondary malignant. Disease-free survival at 3 years was 91%. | Maxwell, Adv Radiat Oncol 2023
